▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / CASIF

CASIF — CASI Pharmaceuticals, Inc.

—
OTC · Health Care · Pharmaceuticals · CIK 1962738 ·
Last close
$0.15
Market Cap
$3.08M
52W High
$0.28
52W Low
$0.05
ADV30
16,851
Next earnings
—
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc?RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 7,222,000 3,693,000 -11,654,000 -13,043,000 25,650,000 5,632,000 62,932,000
Sep 2025 3,075,000 706,000 -10,244,000 -10,883,000 24,462,000 4,685,000 53,054,000
Jun 2025 4,175,000 2,058,000 -10,710,000 -13,375,000 31,202,000 6,740,000 51,512,000
Mar 2025 6,240,000 3,619,000 -10,233,000 -10,750,000 40,821,000 10,897,000 48,891,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-735,090,000
Inventory
$2,611,000
Receivables
$2,609,000
ST Investments
$0
EBIT TTM
$-42,538,000
Pretax Income TTM
$-47,131,000
Interest Exp TTM
$840,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$20,712,000
EBITDA
$-41,589,000
Free Cash Flow
$-650,750
Enterprise Value
$24,115,146
Total Cash
$5,632,000
Total Debt
$27,486,000
Shares Out
20,555,873
Trailing EPS
$-2.59
Book Value
$-1.81
ROE
—
ROA
-67.5%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 20,712,000 -42,846,000 -48,058,000 25,650,000 62,932,000 — -20,754,000
Dec 2024 28,537,000 -39,212,000 -39,258,000 53,674,000 51,823,000 — -29,224,000
Dec 2023 33,879,000 -25,280,000 -26,938,000 75,268,000 51,103,000 — -19,967,000
Dec 2022 43,107,000 -26,491,000 -41,014,000 96,234,000 29,302,000 — -21,088,000
Dec 2021 — — — — — — —

Peers — same industry

TickerNameMarket CapLastDaily %
AVCRF Avricore Health Inc. $3.29M $0.03 —
LSBCF LakeShore Biopharma Co., Ltd. $2.88M $0.07 —
AZTR Azitra, Inc. $3.40M $0.21 —
SHPH Shuttle Pharmaceuticals Holdings, Inc. $3.43M $0.59 —
BIXT BIOXYTRAN, INC $3.47M $0.03 —

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →